Thursday, July 9, 2026

pharma · Melanoma · Tumor · NKTR

Nektar Therapeutics UK

Nektar Therapeutics is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker NKTR. Primary therapeutic focus areas include Melanoma, Tumor, Renal Cell Carcinoma, Alopecia Areata, Pneum

455 Mission Bay Boulevard South, San Francisco, California 94158, US HQ
1990 Founded
610 Employees
Public company Type
NKTR · NYSE Ticker
Company details
Status
Public
HQ
455 Mission Bay Boulevard South, San Francisco, California 94158, US
Founded
1990
Employees
610
Programs
57
Drugs
31
Patents
423
Clinical program

Rezpegaldesleukin

Phase 2 · small molecule · Alopecia Areata

Rezpegaldesleukin for Alopecia Areata is a Phase 2 program (small_molecule) at Nektar Therapeutics UK Limited with 1 ClinicalTrials.gov record(s).

Internal code 23-358-06

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Nektar Therapeutics UK Limited
Phase
Phase 2
Modality
small_molecule
Indication
Alopecia Areata
Status
active
Trials
1

Clinical trials